PPT-A phase III trial of adjuvant capecitabine in breast cancer

CREATE XJBCRG 04 C apecitabine for RE sidual cancer as A djuvant T h E rapy San Antonio Breast Cancer Symposium December 812 2015 Lee S J 1 Toi M 2 Lee ES. Sigrun Hallmeyer, MD. Oncology Specialists, SC. Director, Oncology Specialists Research Institute. Chair, Cancer Committee ALGH. Primary goals of systemic treatment for metastatic breast cancer. Prolongation of survival,. Joyce O'Shaughnessy, MD. Kimberly Blackwell, MD. Hope . Rugo. , MD. Reminder: feedback is appreciated. You will be prompted at the end for your feedback.. Updates on Chemotherapy and Other Novel Agents. Dr. Courtney A. Vito, MD, FACS. Assistant Clinical Professor of . Surgcal. Oncology. City of Hope National Medical Center . 12/8/2014. Disclosures. No relevant financial disclosures. Serve as PI for the . Rachna Raman MD MS. Hematology and Medical Oncology. Bon Secours Cancer Institute at St. Mary’s Hospital. Objectives. Risk factors . Screening guidelines and controversies. Screening and management of patients at high risk for breast cancer. Cancer-Treatment-Induced Bone Loss (CTIBL). Clodronate and Bone Mineral Density (. Hip. ). Bone Mineral Density Substudy --ABCSG-12: Effect of Zoledronic Acid. Percent Change, Lumbar Spine. Denosumab for CTIBL (. ASCO-CAP Recommendations For HER2 Testing in Breast Cancer. Criteria For Reporting HER2 Test Results . as Positive. Criteria for Reporting HER2 Test Results . as Negative. Criteria for Reporting Equivocal Results . Management of HER2 Over-Expressed Breast Cancer in the Adjuvant, Neoadjuvant, and Metastatic settings Christy A Russell, MD Keck School of Medicine University of Southern California Metastatic Breast Cancer Antonella Brunello . Kwok-Leung Cheung. Disclosure. No . conflict. of . interests. Learning objectives. To . discuss the pros and cons of adjuvant chemotherapy for breast cancer in the elderly. To . across the breast cancer therapy spectrum. Phase I. Phase II. Phase III. Registration. Approval. HER2+ Breast Cancer. Extended adjuvant. Neratinib monotherapy. Metastatic. Monotherapy or combination therapy. Andreas Makris. Mount Vernon Cancer Center. Royal College of Radiologists, London, 17. th. June 2015. CMF. ACx4. NSABP B15. FAC. FEC. FE. 100. C. FASG05. Ax4.  CMFx4 . alt vs seq. Ex4.  CMFx4. Rajiv Doddamani. . PGY – 3, Internal Medicine . . St. Joseph Mercy Ann Arbor . Learning objectives . Explain the principles of breast cancer screenings . Professor of Medicine and Oncology. Karmanos Cancer Institute. Wayne State University. Breast Cancer 101. Biopsy +. Lumpectomy + RT. Mastectomy. SLNBx. ALND (> 3+ micro or macro preop and bx +). Standard, . Azeez Farooki, MD. Attending Physician, Clinical Member. Memorial Sloan Kettering Cancer Center. New York, NY. Objectives. Elucidate the problem of aromatase inhibitor induced bone loss and increased risk of fractures in breast cancer. . Breast Cancer | . Epidemiology- Australia. Australian Institute of Health and Welfare 2014. ACIM (Australian Cancer Incidence and Mortality) Books. Canberra. AIHW. Overall is the third leading cause of cancer.